Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

The emergency department is a pressure cooker where stressed patients, psychological distress and violence combine into a ...

Coronation Street has aired a devastating cliffhanger for Debbie Webster tonight, following her dramatic court sentencing.

Understanding seizure causes and their warning signs together with when to seek medical help is crucial because not all ...

The emergency department is a pressure cooker where stressed patients, psychological distress and violence combine into a ...

Bayer AG’s oral factor XIa inhibitor asundexian significantly reduced ischemic stroke by 26% in patients following a noncardioembolic ischemic stroke or high-risk transient ischemic attack in the ...

Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...

If you've ever suffered a sudden onset of dizziness, or the vision in one eye is quickly distorted or blurred, you may have ...

In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective ...